Autonomix Medical, Inc. is a medical device company focused on advancing technologies to develop how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity. It is developing its technology for pancreatic cancer and pancreatitis, conditions that can cause debilitating pain and need an effective solution. Its technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Its development efforts are divided into two parts: diagnostic sensing and therapeutic radiofrequency ablation. The Company is developing Autonomix system, which is primarily catheter-based, meaning that its sensing equipment is delivered to its targeted location via a lumen within the body.
Ticker SymbolAMIX
Company nameAutonomix Medical Inc
IPO dateJan 29, 2024
CEOHauser (Bradley)
Number of employees8
Security typeOrdinary Share
Fiscal year-endJan 29
Address21 Waterway Ave, Suite 300
CityTHE WOODLANDS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code77380
Phone18322777816
Websitehttps://autonomix.com/
Ticker SymbolAMIX
IPO dateJan 29, 2024
CEOHauser (Bradley)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data